Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer

BACKGROUND: The KRAS mutation is the driving force of pancreatic ductal adenocarcinoma (PDAC). Downstream effectors of KRAS signal pathways are crucial to the development of PDAC. The purpose of this study was to investigate the relationship between KRAS mutation and transgelin-2. Transgelin-2 is hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yan, Peng, Wenfang, He, Weiwei, Luo, Man, Chang, Guilin, Shen, Jiping, Zhao, Xiaoping, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056937/
https://www.ncbi.nlm.nih.gov/pubmed/30041673
http://dx.doi.org/10.1186/s13046-018-0818-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056937/
https://www.ncbi.nlm.nih.gov/pubmed/30041673
http://dx.doi.org/10.1186/s13046-018-0818-z

Ejemplares similares